1-8 of 8
Danelle F. James, M.D.
Close
Sort by
Journal Articles

Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis

Michael Y. Choi, MD, Januario E. Castro, M.D., Sheila Hoff, RN, Hongying Li, PhD, Laura Rassenti, PhD, Danelle F. James, M.D., M.A.S., Karen Messer, PhD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 5299.
https://doi.org/10.1182/blood.V122.21.5299.5299
Published: 2013
Journal Articles

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

Jan A. Burger, MD, PhD, Michael J. Keating, MD, William G. Wierda, MD, PhD, Julia Hoellenriegel, Alessandra Ferrajoli, M.D., Stefan Faderl, MD, Susan Lerner, MS, Gracy Zacharian, Xuelin Huang, PhD, Danelle F. James, M.D., Joseph J. Buggy, PhD, Hagop M Kantarjian, Susan M. O'Brien
Journal: Blood
Blood (2012) 120 (21): 187.
https://doi.org/10.1182/blood.V120.21.187.187
Published: 2012
Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naìˆve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD, PhD, Jan A. Burger, MD, PhD, Kristie A. Blum, MD, Jeff Sharman, MD, Barbara Grant, MD, Jeffrey A. Jones, MD, MPH, William G. Wierda, MD, Ph.D., Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Anh Tran, Fong Clow, ScD, Lori Kunkel, MD, Danelle F. James, M.D, Susan O'Brien, MD
Journal: Blood
Blood (2012) 120 (21): 189.
https://doi.org/10.1182/blood.V120.21.189.189
Published: 2012
Journal Articles

Eradication of Minimal Residual Disease Using Alemtuzumab Consolidation After High-Dose Methyl-Prednisolone Plus Rituximab (HDMP-R) Is Safe, Effective and Induces Long Term Remission in Chronic Lymphocytic Leukemia

Januario E. Castro, M.D., Lina M. Ariza-Serrano, M.D. (c), Juan S. Barajas-Gamboa, M.D., Julio A. Diaz-Perez, M.D., M.S., Danelle F. James, M.D., Amine Ale-Ali, Pharm.D., Thomas J. Kipps, M.D., Ph.D
Journal: Blood
Blood (2011) 118 (21): 2866.
https://doi.org/10.1182/blood.V118.21.2866.2866
Published: 2011
Journal Articles

Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium

Danelle F. James, M.D., Jennifer R. Brown, MD, PhD, Lillian Werner, William G. Wierda, MD, PhD, Jaqueline C. Barrientos, MD, Januario Castro, MD, Andrew Greaves, Laura Z. Rassenti, Ph.D., Kanti R. Rai, MD, Donna Neuberg, ScD, Thomas J. Kipps, M.D., Ph.D
Journal: Blood
Blood (2011) 118 (21): 291.
https://doi.org/10.1182/blood.V118.21.291.291
Published: 2011
Journal Articles

Treatment of Chronic Lymphocytic Leukemia Patients with Lenalidomide Induces Down-Regulation of miR342-3p Associated with Over-Expression of Tumor Suppressor RASSF4,

Emanuela M. Ghia, PhD, Lillian Werner, Danelle F. James, M.D., Donna Neuberg, ScD, Laura G Corral, Senior, Scientist, Laura Z. Rassenti, Ph.D., Carlo M. Croce, MD, Thomas J. Kipps, M.D., Ph.D
Journal: Blood
Blood (2011) 118 (21): 3885.
https://doi.org/10.1182/blood.V118.21.3885.3885
Published: 2011
Journal Articles

Phenotypic Changes Associated with Acute Reductions In Leukemia Cell Counts In Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Lenalidomide as Initial Therapy

Danelle F. James, M.D., M.A.S., Jennifer R Brown, MD, PhD, Lillian Werner, Januario E Castro, M.D, Kanti R. Rai, MD, William G. Wierda, MD, PhD, Andrew Greaves, Laura Z Rassenti, PhD, Donna Neuberg, ScD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 59.
https://doi.org/10.1182/blood.V116.21.59.59
Published: 2010
Journal Articles

Ofatumumab and High-Dose Methylprednisolone Is An Effective Salvage Treatment for Heavily Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic Leukemia: Single Institution Experience

Januario E Castro, M.D, Juan Sebastian Barajas-Gamboa, M.D, Johanna Melo-Cardenas, B.Sc, Rosa N Paz, Cesar Bernal-Corzo, Amine Ale-Ali, Pharm., D., Danelle F. James, M.D, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 4638.
https://doi.org/10.1182/blood.V116.21.4638.4638
Published: 2010